Table 1. Baseline characteristics.
| Characteristic | Total (n = 175) No. (%) |
Only ADJ (n = 131) No (%) |
ADJ with DZR (n = 44) No. (%) |
p-value |
|---|---|---|---|---|
| Age (yr)* | 53 (22–70) | 53 (22–70) | 53 (31–64) | 0.889 |
| ≥ 55 | 74 (42.3) | 55 (42.0) | 19 (43.2) | |
| < 55 | 101 (57.7) | 76 (58.0) | 25 (56.8) | |
| Hypertension | 0.541 | |||
| Yes | 38 (21.7) | 27 (20.6) | 11 (25.0) | |
| No | 137 (78.3) | 104 (79.4) | 33 (75.0) | |
| DM | 0.204 | |||
| Yes | 29 (16.6) | 19 (14.5) | 10 (22.7) | |
| No | 146 (83.4) | 112 (85.5) | 34 (77.3) | |
| Overweight | 0.707 | |||
| Yes | 44 (25.1) | 32 (24.4) | 12 (27.3) | |
| No | 131 (74.9) | 99 (75.6) | 32 (72.7) | |
| Hyperlipidemia | 0.981 | |||
| Yes | 40 (22.9) | 30 (22.9) | 10 (22.7) | |
| No | 135 (77.1) | 101 (77.1) | 34 (77.3) | |
| Smoking† | 0.411‡ | |||
| Ever-smoker | 20 (11.4) | 17 (13.0) | 3 (6.8) | |
| Nonsmoker | 155 (88.6) | 114 (87.0) | 41 (93.2) | |
| Pathologic stage | 0.963 | |||
| I | 32 (18.3) | 24 (18.3) | 8 (18.2) | |
| II | 117 (66.9) | 87 (66.4) | 30 (68.2) | |
| III | 26 (14.9) | 20 (15.3) | 6 (13.6) | |
| Operation type | 0.365 | |||
| BCS with SLNB | 42 (24.0) | 34 (26.0) | 8 (18.2) | |
| BCS with ALND | 56 (32.0) | 41 (31.3) | 15 (34.1) | |
| SM with SLNB | 24 (13.7) | 20 (15.3) | 4 (9.1) | |
| MRM | 53 (30.3) | 36 (27.5) | 17 (38.6) | |
| Hormone receptor | 0.316 | |||
| Negative | 96 (54.9) | 69 (52.7) | 27 (61.4) | |
| Positive | 79 (45.1) | 62 (47.3) | 17 (38.6) | |
| Radiation before trastuzumab | 0.334 | |||
| Yes | 108 (61.7) | 78 (59.5) | 30 (68.2) | |
| No | 67 (38.3) | 53 (40.5) | 14 (31.8) | |
| Regimen | 0.104 | |||
| AC followed by trastuzumab | 74 (42.3) | 60 (45.8) | 14 (31.8) | |
| AC+docetaxel followed by trastuzumab | 101 (57.7) | 71 (54.2) | 30 (68.2) | |
| LVEF (%)§ | 59.76 ± 3.48 | 59.85 ± 3.66 | 59.48 ± 2.89 | 0.055 |
| ≥ 60 | 70 (40.0) | 47 (35.9) | 23 (52.3) | |
| < 60 | 105 (60.0) | 84 (64.1) | 21 (47.7) |
ADJ=anthracycline-based adjuvant chemotherapy followed by trastuzumab; DZR=dexrazoxane; DM=diabetes mellitus; BCS=breast-conserving surgery; SLNB=sentinel lymph node biopsy; ALND=axillary lymph node dissection; SM=simple mastectomy; MRM =modified radical mastectomy; AC = doxorubicin with cyclophosphamide; LVEF=left ventricular ejection fraction.
*Median (range); †Smoking was classified as nonsmokers (those with a lifetime exposure of 100 cigarettes or less) and ever-smokers (those with a lifetime exposure of more than 100 cigarettes); ‡Fisher exact test; §Mean±SD.